source
- Agios halts development of tebapivat for low-risk MDS after disappointing Phase 2b dataAgios Pharmaceuticals announced it will discontinue development of its pyruvate kinase activator tebapivat for patients with low-risk myelodysplastic syndromes (MDS). The decision follows the relea…
- Allogene CEO David Chang to step down after eight years; former Esperion chief joins PhlowLongtime Allogene chief executive David Chang announced he will leave the role at the end of June, concluding an eight‑year tenure leading the cell‑therapy developer. The company said a successor…